PDE Inhibition and cognition enhancement

Bibliography

• Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011;91:651-90
   PubMed Web of Science ®Google Scholar
• Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520
   PubMed Web of Science ®Google Scholar
• Halene TB, Siegel SJ. PDE inhibitors in psychiatry–future options for dementia, depression and schizophrenia? Drug Discov Today 2007;12:870-8
   PubMed Web of Science ®Google Scholar
• Rahimi R, Ghiasi S, Azimi H, A review of the herbal phosphodiesterase inhibitors; future perspective of new drugs. Cytokine 2010;49:123-9
   PubMed Web of Science ®Google Scholar
• Schoffelmeer AN, Wardeh G, Mulder AH. Cyclic AMP facilitates the electrically evoked release of radiolabelled noradrenaline, dopamine and 5-hydroxytryptamine from rat brain slices. Naunyn Schmiedebergs Arch Pharmacol 1985;330:74-6
   PubMed Web of Science ®Google Scholar
• Nishi A, Snyder GL. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. J Neurosci 2010;114:6-16
   Google Scholar
• Blokland A, Boess F. Use of behavioral and LTP models in the development of memory-improving drugs. Expert Opin Drug Discov 2008;3:1067-80
   PubMed Web of Science ®Google Scholar
• Raymond CR. LTP forms 1, 2 and 3: different mechanisms for the “long” in long-term potentiation. Trends Neurosci 2007;30:167-75
   PubMed Web of Science ®Google Scholar
• Deshmukh R, Sharma V, Mehan S, Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine – a PDE1 inhibitor. Eur J Pharmacol 2009;620:49-56
   PubMed Web of Science ®Google Scholar
• Boess FG, Hendrix M, Van der Staay FJ, Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004;47:1081-92
   PubMed Web of Science ®Google Scholar
• Rutten K, Prickaerts J, Blokland A. Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol Learn Mem 2006;85:132-8
   PubMed Web of Science ®Google Scholar
• van der Staay FJ, Rutten K, Barfacker L, The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 2008;55:908-18
   PubMed Web of Science ®Google Scholar
• Reneerkens OA, Rutten K, Steinbusch HW, Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 2009;202:419-43
   PubMed Web of Science ®Google Scholar
• Prickaerts J, de Vente J, Honig W, Increasing hippocampal cGMP, but not cAMP, levels improves memory performance in an object recognition task in rats. Eur J Pharmacol 2002;436:83-7
   PubMed Web of Science ®Google Scholar
• Marte A, Pepicelli O, Cavallero A, In vivo effects of phosphodiesterase inhibition on basal cyclic guanosine monophosphate levels in the prefrontal cortex, hippocampus and cerebellum of freely moving rats. J Neurosci Res 2008;86:3338-47
   Google Scholar
• Schmidt CJ. Phosphodiesterase inhibitors as potential cognition enhancing agents. Curr Top Med Chem 2010;10:222-30
   PubMed Web of Science ®Google Scholar
• Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010;59:367-74
   PubMed Web of Science ®Google Scholar
• Menniti FS, Chappie TA, Humphrey JM, Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 2007;8:54-9
   PubMedGoogle Scholar
• Giralt A, Saavedra A, Carreton O, Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum Mol Genet 2011;20:4232-47
   PubMed Web of Science ®Google Scholar
• Bruno O, Fedele E, Prickaerts J, GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol 2011;164:2054-63
   PubMed Web of Science ®Google Scholar
• Reyes-Irisarri E, Markerink-Van Ittersum M, Mengod G, Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. Eur J Neurosci 2007;25:3332-8
   PubMed Web of Science ®Google Scholar
• Domek-Lopacinska K, Strosznajder JB. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 2008;1216:68-77
   PubMed Web of Science ®Google Scholar
• Krokera KS, Rastb G, Giovanninic R, Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP. Neuropharmacology 2012;62:1964-74
   Google Scholar
• Xu Y, Zhang HT, O'Donnell JM. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders. Handb Exp Pharmacol 2011;204:447-85
   Google Scholar
• Rodefer JS, Saland SK, Eckrich SJ. Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. Neuropharmacology 2012;62:1182-1190
   PubMed Web of Science ®Google Scholar
• Burgin AB, Magnusson OT, Singh J, Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 2010;28:63-70
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/
   Google Scholar